Frontlight ResearchEarly access
SuspendedEarly phase 1
Autologous CAR-T Cells (WD-01) for Metastatic Colorectal Cancer
Key facts
- Who runs it
- Wondercel Biotech (ShenZhen)
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Suspended
- Phase
- Early phase 1
- People taking part
- 30 people, planned
- Started
- 18 May 2025
- Expected to end
- 30 Dec 2029
- Type of study
- Interventional
- Treatments tested
- An armored GCC targeting WD-01 CAR-T to treat cancer patients Other Name:
- Record updated
- 7 May 2026
- Why it stopped
- Because the implementation of the new regulation policy by the Chinese authority
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Pathologically confirmed colorectal cancer. Immunohistochemistry (IHC) assessment shows GCC expression in tumor lesions of ≥1+ in an average of over 40% of the area (evaluated by randomly selecting at least five tumor regions); Patients with metastatic colorectal cancer who have failed second-line treatment; At least one measurable extracranial lesion per RECIST version 1.1 criteria. Expected survival of ≥90 days; Normal function of major organs, meeting the following criteria:
- ECOG performance status of 0-1 or KPS score >70
- Hematology parameters meeting: Hemoglobin (HB) ≥80 g/L, Absolute Neutrophil Count (ANC) ≥1.5 × 10\^9/L, Platelets (PLT) ≥80 × 10\^9/L, Lymphocytes (LY) ≥0.5 × 10\^9/L
- Biochemistry parameters meeting: Total Bilirubin (TBIL) ≤2.0 × ULN (upper limit of normal); ALT and AST ≤2.5 × ULN; Serum Creatinine (Cr) ≤1 × ULN, Creatinine Clearance Rate >40 mL/min (by Cockcroft-Gault formula)
- Left ventricular ejection fraction >55%. Women of childbearing potential must have a negative pregnancy test (serum or urine) within 7 days prior to enrollment and agree to use appropriate contraception during the study and for 8 weeks after the last CAR-T administration (women who have undergone sterilization or have been postmenopausal for at least 2 years are considered not of childbearing potential); Voluntary participation in the study, with signed informed consent, good compliance, and willingness to cooperate with follow-up
Who cannot take part
- Pregnant or lactating women. Receipt of small molecule chemotherapy, targeted agents, other investigational drugs, or monoclonal antibodies within 14 days prior to cell collection for enrollment; Participation in other clinical trials within 4 weeks prior to the start of this study; Uncontrolled hypertension that cannot be adequately managed with a single antihypertensive drug (systolic BP >160 mmHg, diastolic BP >100 mmHg), myocardial ischemia or infarction of grade ≥1, arrhythmia of grade ≥1 (including QT interval ≥440 ms), or cardiac insufficiency; Long-standing, unhealed wounds or fractures. History of substance abuse that cannot be discontinued or a history of psychiatric disorders; Severe intestinal adhesions, bowel obstruction, or conditions that may cause bowel perforation or abdominal wall fistula after treatment; Uncontrolled or active fungal, bacterial, viral, or other infections. Grade ≥2 hematologic toxicity or grade ≥3 non-hematologic toxicity at enrollment as per NCI-CTCAE version 5.0 criteria; Known HIV infection or active hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV positive) infection; Presence of indwelling catheters or drainage tubes (e.g., biliary drainage tubes or thoracic/abdominal drainage tubes or pericardial catheters). Use of specialized central venous catheters is permitted; Severe malnutrition (for patients <70 years, BMI <18.5 kg/m\^2; for patients ≥70 years, BMI <20 kg/m\^2); History of severe allergic reactions to key therapeutic agents in this study (including fludarabine, cyclophosphamide, mesna, tocilizumab, and anti-infective drugs used during preconditioning); History of disseminated intravascular coagulation (DIC), deep vein thrombosis, or pulmonary embolism within 6 months prior to enrollment; History of autoimmune diseases that cause terminal organ damage or require systemic immunosuppressive/systemic disease-modifying drugs within 2 years prior to enrollment (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus); Any disease that may interfere with the safety or efficacy assessment of the study treatment; Female participants who are unwilling to use contraception from the time of consent until 6 months after completing CAR-T cell infusion
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is an investigator initiated trial to assess the efficacy and safety of a GCC-targeting CAR-T therapy (WD-01) in the metastatic colorectal cancer.
The group in the trial
- Single dose injection of WD-01Treatment being tested
Dose escalation will be performed for the single dose injection of WD-01 for treating mCRC
Treatment: An armored GCC targeting WD-01 CAR-T to treat cancer patients Other Name:
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Clinical Study on the Safety and Efficacy of GCC Targeting CAR-T Cells (WD-01) for Metastatic Colorectal Cancer
- Record updated
- 7 May 2026